Navigation Links
Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team

SAN FRANCISCO, Oct. 29, 2012 /PRNewswire/ -- Principia Biopharma, Inc., a privately-held biopharmaceutical company focused on advancing best-in-class medicines in immunology, autoimmune diseases, and oncology announced that it successfully met its milestone obligations and received its second tranche of funding totaling $12.5 million in July 2012. The investment was led by existing investors New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.  In February 2011, Principia completed a tiered Series A round of financing totaling $36.3 million and received the first tranche of $12 million that same month.  Proceeds from this most recent financing will be used to advance Principia's lead molecule towards the clinic and to develop additional programs enabled by the company's reversible covalent platform.


Martin Babler, CEO of Principia, says, "We are pleased to complete the closing of our second tranche as it provides the necessary funding for Principia to advance our lead compound toward our first clinical trials in 2013. We appreciate the continued support from our current investors as we invest in important treatments for cancer and autoimmune disorders."


As part of Principia's growth and its initiatives to bring new medicines to patients, the company has expanded its senior management team with the hiring of Jens Oliver Funk, M.D. as Chief Scientific Officer (CSO). Dr. Funk has nearly 20 years of experience in biomedical research and management and joined Principia from Merck Serono, Merck KGaA where he was Senior Vice President of R&D and Global Head of the Therapeutic Area Oncology. Dr. Funk led the advancement of Merck Serono's oncology portfolio and successfully built a dynamic organization in Boston and Darmstadt, Germany, focusing on small molecule and biologics discovery in the fields of cancer and cancer immunotherapy.  Dr. Funk has brought more than ten novel drug candidates into clinical development and contributed to the approval of Erbitux® in various indications in Europe.

Earlier in his career Dr. Funk worked in academia for ten years at UCSF, the Fred Hutchinson Cancer Research Center, and the Universities of Erlangen and Munich in research and clinical positions.  Dr. Funk received his medical and scientific training at Stanford University, the University of Edinburgh and the University of Lubeck, where he graduated with an M.D. Dr. Funk has co-authored numerous scientific articles in international peer-reviewed journals and is board certified in dermatology.

Martin Babler continued, "As the company expands and advances its portfolio, Jens Oliver brings significant translational experience both in oncology and autoimmune diseases to the company and will contribute to advancing the programs into the clinic as well as prioritizing the assets from a technical and clinical viewpoint. His experience in R&D and as a clinician make him uniquely qualified to help the company maximize opportunities with its broad portfolio of autoimmune and oncology programs."

"Principia Biopharma has made remarkable progress since its initial funding in 2011," stated Dr. Funk.  "I look forward to working with the team to further develop the platform and drive our lead programs towards clinical trials.  It's truly an exciting time to join the company."

About Principia Biopharma

Principia Biopharma is a private, pre-clinical stage company initially focused on the discovery and development of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. The company expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and its reversible covalent platform.  Principia raised a $36.3 million Series A round of investment from a leading group of health care investors including New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.  For more information, please visit the company's website at

This press release contains certain forward-looking statements that involve risks and uncertainties. Such statements are only predictions based on management's current projections and goals and are subject to a number of factors and uncertainties.  Information in these forward-looking statements is inherently uncertain and the Company's actual results may differ materially from those anticipated in such forward-looking statements.



SOURCE Principia Biopharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron Named Worlds #1 Biopharmaceutical Employer in Science Magazine Annual Survey
2. Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
3. PDL BioPharma Completes Regular Quarterly Dividend Payment
4. Chester County Biopharmaceutical Firm to Expand, Create 151 New Jobs
5. National Press Club to Host "NEWSMAKER" with PhRMA CEO to Discuss Policy, Budget Threats to Biopharmaceutical Research
6. PDL BioPharma to Present at Upcoming Investor Conferences
7. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
8. The Thousand-Year Business Model for a Modern Biopharmaceutical Company
9. BioWorld Launches Enhanced Biopharma News Site with Data, Analysis
10. Biopharmaceutical Service Providers Announce Collaborative Opening of Boston, MA Office
11. New Stroke Drug from ZZ Biotech Produced by Laureate Biopharma
Post Your Comments:
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
Breaking Medicine News(10 mins):